Intercept Pharmaceuticals, Inc. Logo
 
Press Releases
Date Title and Summary View
Sep 19, 2016 New Drug Submission filed to Health Canada for obeticholic acid for PBCSubmission granted priority reviewIf approved, obeticholic acid would represent first new treatment option for PBC in 20 years                      &...
Sep 2, 2016 NEW YORK, Sept. 02, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced management will be participating in the following investor conferences: ...
Aug 17, 2016 NEW YORK, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that the ...
Aug 4, 2016 Ocaliva® (obeticholic acid or OCA) approved by the FDA under the accelerated approval pathway on May 27, 2016Net Ocaliva 2Q sales of $75,000 shipped to patients, $2.7 million recorded as deferred revenueREGENERATE NASH trial tar...
Jul 28, 2016 NEW YORK, July 28, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report its second quarter 2016 financial results prior to the NASDAQ marke...
Jul 6, 2016 NEW YORK, July 06, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) announced today the closing of its previously announced underwritten public offering of $460 million aggregate principal amount of 3.25% convertible senior notes due 2023 (the notes), including the full exercise by the underwriters of an option to pur...
Jun 30, 2016 NEW YORK, June 30, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) announced today the pricing of its previously announced underwritten public offering of $400 million aggregate principal amount of 3.25% convertible senior notes due 2023 (the notes). Intercept has granted the underwriters an option, exercisable for 30 ...
Jun 29, 2016 NEW YORK, June 29, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) announced today that it has commenced an underwritten public offering of $400 million aggregate principal amount of convertible senior notes due 2023 (the notes). RBC Capital Markets, UBS Investment Bank, BofA Merrill Lynch, Citigroup and Credit Suisse ...
Jun 9, 2016 NEW YORK, June 09, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced  the appointment of Sandip Kapadia as Chief Financial Officer. Mr. Kapadia will succ...
Jun 1, 2016 NEW YORK, June 01, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced management will be participating in the following investor conferences: ...
Page:
1
... NextLast
= add release to Briefcase